报价延迟最少15分钟:2026/06/10 19:21 EDT
盘后时段
|
||||
|
1.99 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.72
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.06/--
|
|
企业价值
144.55M
|
| 资产负债 |
|
每股账面净值
-0.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC. |
